These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35315290)

  • 41. Update on molecular mechanisms of corticosteroid resistance in chronic obstructive pulmonary disease.
    Jiang Z; Zhu L
    Pulm Pharmacol Ther; 2016 Apr; 37():1-8. PubMed ID: 26805715
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
    Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology.
    Acerbi D; Brambilla G; Kottakis I
    Pulm Pharmacol Ther; 2007; 20(3):290-303. PubMed ID: 16890465
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [New therapeutic approaches in 2014 in pulmonary medicine: COPD, asthma and lung fibrosis].
    Rochat T; Charbonnier F; Plojoux J
    Rev Med Suisse; 2015 Jan; 11(456-457):129-32, 134. PubMed ID: 25799669
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].
    Sin DD; Man SF; Marciniuk DD; Ford G; FitzGerald M; Wong E; York E; Mainra RR; Ramesh W; Melenka LS; Wilde E; Cowie RL; Williams D; Rousseau R;
    BMC Pulm Med; 2006 Feb; 6():3. PubMed ID: 16460562
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regulation of inflammatory cell function by corticosteroids.
    Belvisi MG
    Proc Am Thorac Soc; 2004; 1(3):207-14. PubMed ID: 16113436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment.
    Pelaia G; Muzzio CC; Vatrella A; Maselli R; Magnoni MS; Rizzi A
    Expert Opin Pharmacother; 2015; 16(13):2009-21. PubMed ID: 26194120
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease.
    Durham AL; Caramori G; Chung KF; Adcock IM
    Transl Res; 2016 Jan; 167(1):192-203. PubMed ID: 26334389
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis and Evaluation of Airway-Targeted PLGA-PEG Nanoparticles for Drug Delivery in Obstructive Lung Diseases.
    Vij N
    Methods Mol Biol; 2020; 2118():147-154. PubMed ID: 32152977
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease.
    Spears M; McSharry C; Thomson NC
    Clin Exp Allergy; 2006 Dec; 36(12):1494-504. PubMed ID: 17177672
    [TBL] [Abstract][Full Text] [Related]  

  • 51. What is in the guidelines about the pharmacological treatment of chronic obstructive pulmonary disease?
    López-Campos JL; Calero Acuña C
    Expert Rev Respir Med; 2013 Apr; 7(2 Suppl):43-51. PubMed ID: 23551023
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes.
    Barnes PJ
    J Allergy Clin Immunol; 2015 Sep; 136(3):531-45. PubMed ID: 26343937
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Corticosteroid treatment in airways narrowing].
    Chazan R
    Pneumonol Alergol Pol; 2008; 76(2):96-100. PubMed ID: 18464224
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.
    Shu D; Li H; Shu Y; Xiong G; Carson WE; Haque F; Xu R; Guo P
    ACS Nano; 2015 Oct; 9(10):9731-40. PubMed ID: 26387848
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epigenetic targets for novel therapies of lung diseases.
    Comer BS; Ba M; Singer CA; Gerthoffer WT
    Pharmacol Ther; 2015 Mar; 147():91-110. PubMed ID: 25448041
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of chronic obstructive pulmonary disease: moving beyond the asthma algorithm.
    Gordon E; Lazarus SC
    J Allergy Clin Immunol; 2009 Nov; 124(5):873-80; quiz 881-2. PubMed ID: 19895979
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhaled simvastatin nanoparticles for inflammatory lung disease.
    Tulbah AS; Pisano E; Scalia S; Young PM; Traini D; Ong HX
    Nanomedicine (Lond); 2017 Oct; 12(20):2471-2485. PubMed ID: 28972463
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Do chronic inhaled steroids alone or in combination with a bronchodilator prolong life in chronic obstructive pulmonary disease patients?
    Sin DD; Man SF
    Curr Opin Pulm Med; 2007 Mar; 13(2):90-7. PubMed ID: 17255798
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Perioperative Pulmonary Medication Management.
    Renew JR; Aniskevich S
    Curr Clin Pharmacol; 2017; 12(3):182-187. PubMed ID: 28925861
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility.
    Perng DW; Wu CC; Su KC; Lee YC; Perng RP; Tao CW
    Lung; 2006; 184(4):217-22. PubMed ID: 17006748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.